FDA Approves New First-Line Standard of Care in Bladder Cancer
(MedPage Today) -- Patients with locally advanced or metastatic bladder cancer have a permanent new first-line standard of care after the FDA granted full approval to the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) regardless...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Bladder Cancer | Cancer | Cancer & Oncology | International Medicine & Public Health